Needham & Company LLC Lowers Pliant Therapeutics (NASDAQ:PLRX) Price Target to $10.00
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) had its price target lowered by equities researchers at Needham & Company LLC from $38.00 to $10.00 in a report released on Monday,Benzinga reports.
Canaccord Genuity Group Reiterates Hold Rating for Pliant Therapeutics (NASDAQ:PLRX)
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “hold” rating restated by research analysts at Canaccord Genuity Group in a note issued to investors on Monday, MarketBeat reports.